Begin main content

Abiraterone (Zytiga) for Prostate Cancer Resubmission - Details

Brand Name Zytiga
Generic Name Abiraterone
Strength 250 mg & 500 mg
Tumour Type Genitourinary
Indication Prostate Cancer
Funding Request Newly diagnosed high-risk metastatic castration sensitive prostate cancer without small-cell histologic features. Patients required to have at least two of the three following high-risk factors: Gleason score of 8 or more, at least 3 bone lesions, and presence of visceral metastasis. Less than 3 months of androgen deprivation therapy (or orchiectomy) for metastatic disease. Eligible for abiraterone therapy.
Review Status Pending
Pre Noc Submission No
NOC Date February 15, 2018
Manufacturer Janssen Inc.
Submitter BC Cancer Agency
Submission Date (Target Date) July 25, 2019
Submission Type New Indication
Prioritization Requested
Stakeholder Input Deadline ‡ August 9, 2019
Check-point meeting (target date)
pERC Meeting (target date)
Initial Recommendation Issued (target date)
Feedback Deadline (target date) ‡
pERC Reconsideration Meeting (target date)
Final Recommendation Issued (target date)
Notification to Implement Issued

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.